{"id":"W2017082986","doi":"10.1038/sj.bjc.6603419","title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Temsirolimus; Medicine; Pharmacodynamics; Rash; Internal medicine; Sirolimus; Everolimus; Adverse effect; Oncology; Pharmacology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Biology; Pharmacokinetics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001096811,0.0009172741,0.001727457,0.0003139506,0.0002653024,0.0004966148,0.0004417539,0.0006572029,0.001402192],"category_scores_gemma":[0.0005730431,0.000364346,0.0006364735,0.0002910485,0.0006332422,0.0003591639,0.0002385256,0.001738263,0.000346476],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004527915,"about_ca_system_score_gemma":0.0009018913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004588729,"about_ca_topic_score_gemma":0.0008875161,"domain_scores_codex":[0.9996686,0.0001678545,0.00001595345,0.00004987678,0.00004079273,0.00005693685],"domain_scores_gemma":[0.9995281,0.00007429135,0.00006773516,0.00005093345,0.00003203313,0.0002470467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3518754,0.1074155,0.02390142,0.0005132961,0.001046232,0.000889383,0.0005235143,0.007062239,0.3735975,0.0004280047,0.002595827,0.1301517],"study_design_scores_gemma":[0.1735573,0.7556289,0.04209594,0.0000196373,0.0002925563,0.0009490868,0.00009334213,0.003860116,0.01974959,0.000219513,0.003487442,0.00004660762],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977375,0.0005156252,0.00040121,0.0001137291,0.00002466819,0.0006514043,0.0001803052,0.00002496899,0.0003506881],"genre_scores_gemma":[0.9941733,0.0007021177,0.001554209,0.0003022122,0.00006398586,0.001087908,0.001132746,0.00001588038,0.000967596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001727457,"threshold_uncertainty_score":0.005800605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02542672549639566,"score_gpt":0.4100298367940532,"score_spread":0.3846031112976576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}